Day One Biopharmaceuticals Inc.(DAWN)

21.53+0.000.00%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Market Outlook: Canada not in recession despite weak growth
  Bloomberg · 06-26
  Market Outlook: Canada not in recession despite weak growth
- Incyte Targets KRAS G12D Pancreatic Cancer With New Phase 3 DAWN-303 Trial
  TIPRANKS · 05-09
  Incyte Targets KRAS G12D Pancreatic Cancer With New Phase 3 DAWN-303 Trial
- Day One Biopharmaceuticals Completes Merger, Goes Private
  TIPRANKS · 04-23
  Day One Biopharmaceuticals Completes Merger, Goes Private
- Day One Biopharmaceuticals asks Nasdaq to delist shares after merger closes
  Reuters · 04-23
  Day One Biopharmaceuticals asks Nasdaq to delist shares after merger closes
- Servier completes acquisition of Day One for $21.50 per share
  Reuters · 04-23
  Servier completes acquisition of Day One for $21.50 per share
- Servier Completes the Acquisition of Day One Biopharmaceuticals
  THOMSON REUTERS · 04-23
  Servier Completes the Acquisition of Day One Biopharmaceuticals
- NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
  Reuters · 04-23
  NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
- JonesTrading Sticks to Its Hold Rating for Day One Biopharmaceuticals (DAWN)
  TIPRANKS · 04-07
  JonesTrading Sticks to Its Hold Rating for Day One Biopharmaceuticals (DAWN)
- Day One downgraded to Neutral from Overweight at JPMorgan
  TIPRANKS · 03-11
  Day One downgraded to Neutral from Overweight at JPMorgan
- HC Wainwright Downgrades Day One Biopharmaceuticals to Neutral From Buy, Adjusts PT to $21.50 From $22
  MT Newswires Live · 03-10
  HC Wainwright Downgrades Day One Biopharmaceuticals to Neutral From Buy, Adjusts PT to $21.50 From $22
- Day One Biopharm Cut to Neutral From Outperform by Wedbush
  Dow Jones · 03-09
  Day One Biopharm Cut to Neutral From Outperform by Wedbush
- U.S. RESEARCH ROUNDUP-Dow, Oracle, Shopify
  Reuters · 03-09
  U.S. RESEARCH ROUNDUP-Dow, Oracle, Shopify
- Day One Biopharmaceuticals Inc : TD Cowen Cuts to Hold From Buy; Cuts Target Price to $21.5 From $24
  THOMSON REUTERS · 03-09
  Day One Biopharmaceuticals Inc : TD Cowen Cuts to Hold From Buy; Cuts Target Price to $21.5 From $24
- Day One Biopharma Earnings Call Highlights Ojemda Surge
  TIPRANKS · 03-08
  Day One Biopharma Earnings Call Highlights Ojemda Surge
- Brodsky & Smith probes Day One Biopharmaceuticals board over Servier sale deal
  Reuters · 03-07
  Brodsky & Smith probes Day One Biopharmaceuticals board over Servier sale deal
- BUZZ-U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
  Reuters · 03-07
  BUZZ-U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
- Top Midday Gainers
  MT Newswires Live · 03-07
  Top Midday Gainers
- Top Midday Stories: Gap Falls on Fiscal Q4 Results; Shell-Venezuela Oil Deals; Jefferies Calls Western Alliance Suit 'Without Merit'
  MT Newswires Live · 03-07
  Top Midday Stories: Gap Falls on Fiscal Q4 Results; Shell-Venezuela Oil Deals; Jefferies Calls Western Alliance Suit 'Without Merit'
- Day One Biopharm Cut to Hold From Buy by Needham
  Dow Jones · 03-07
  Day One Biopharm Cut to Hold From Buy by Needham
- BUZZ-U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
  Reuters · 03-06
  BUZZ-U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
Company Profile
Company Name
Day One Biopharmaceuticals Inc.
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.dayonebio.com;ir.dayonebio.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
- 05-15
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 05-15
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 04-23
  Delisting
  Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
  Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
- 04-23
  Employee Stock Ownership
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 04-23
  Employee Stock Ownership
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 04-23
  Employee Stock Ownership
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 04-23
  Employee Stock Ownership
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 04-23
  Employee Stock Ownership
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 04-23
  Employee Stock Ownership
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
  Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 04-23
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 04-17
  [Rev.]Annual Report
  Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
  Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
- 04-07
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 03-09
  Major Issues Report
  Form 8-K/A - Current report: [Amend]
  Form 8-K/A - Current report: [Amend]
- 03-06
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 03-02
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report

1D
5D
Day
Week
Month

Loading ...

High

21.53

Open

21.53

Volume%

0.00

Low

21.53

T/O Rate

0.00%

To The Moon

Day One Biopharmaceuticals Inc.(DAWN)

Company Profile

Most Discussed